1.Bevacizumab in frontline chemotherapy improved the survival outcome for advanced ovarian clear cell carcinoma:a multicenter retrospective analysis
Shinichi TATE ; Toshiyuki SEKI ; Kyoko NISHIKIMI ; Youichi UNNO ; Mizue ITOI ; Sadatomo IKEDA ; Nobuhisa YOSHIKAWA ; Hidehiko AKASHI ; Eitaro SUZUKI ; Naotake TANAKA ; Takashi HIRAKAWA ; Hiroaki KAJIYAMA ; Hirokuni TAKANO ; Kosuke YOSHIHARA ; Kaori KOGA ; Aikou OKAMOTO ; Makio SHOZU
Journal of Gynecologic Oncology 2025;36(5):e80-
Objective:
Advanced ovarian clear cell carcinoma (OCCC) is associated with poor outcomes owing to chemoresistance. Bevacizumab (Bev) is increasingly being used to treat advanced ovarian cancer; however, its efficacy in OCCC remains unclear. This study evaluated the treatment outcomes of frontline bevacizumab chemotherapy in patients with OCCC.
Methods:
This retrospective multi-institutional study included patients diagnosed with advanced OCCC at eight institutions in Japan between 2008 and 2018. Patients were categorized into pre and post-market groups based on the Bev approval dates. Progressionfree survival (PFS) and overall survival (OS) were analyzed using univariate and multivariate methods. Additionally, patients were classified into Bev-treated (Bev+) and non-Bev-treated (Bev−) groups, and their prognoses were compared.
Results:
A total of 96 patients were in the pre-market group and 82 in the post-market group. The post-market group had a significantly higher proportion of patients with poor performance status and patients who underwent interval debulking surgery (p<0.01 and p<0.01, respectively). Univariate analysis demonstrated a better PFS in the post-market group (p=0.041). In multivariate analysis, better PFS (hazard ratio [HR]=0.52; p=0.002) and OS (HR=0.47; p=0.002) were observed in the post-market group than in the pre-market group.Bev+ patients had significantly better PFS and OS than Bev− patients in univariate (p<0.001 and p<0.001, respectively) and multivariate analyses (PFS: HR=0.36; p<0.001 and OS:HR=0.21; p=0.001, respectively).
Conclusion
Incorporating Bev into frontline chemotherapy may improve outcomes in patients with advanced OCCC.
2.Apron Improvement to the Benefit of Geriatric Health Facility User Who Spills Food
Kaori TAKANO ; Yuri NARABU ; Naoko KANEKO ; Koko MASUYAMA
Journal of the Japanese Association of Rural Medicine 2012;61(1):27-31
This paper reports our saccess in improving an apron used by a hemiplegic man when eating to protect clothes in a geriatric health services facility. The improved apron is useful at home, and helpful for caregivers. He needed assistance during meals and spilled food so frequently that clothes had to be changed after each meal. Frequent changes of clothes meant big burden for persons who looked after him at his home. His wife said, “Changing clothes after every meal will be very troubles some”, Sowe triedto improve the apron by use of cheap and easily available material. After trial and error we succeeded in making the apron that pleased both him and his family.


Result Analysis
Print
Save
E-mail